Maris, J. M. Recent advances in neuroblastoma. N. Engl. J. Med. 3622202–2211 (2010).
Google Scholar
London, W. B. et al. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children’s Oncology Group early-phase trials. Cancer 1234914–4923 (2017).
Google Scholar
Pearson, A. D. J. et al. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration. EUR. J. Cancer 157198–213 (2021).
Google Scholar
Moreno, L. et al. Outcome of children with relapsed or refractory neuroblastoma: a meta-analysis of ITCC/SIOPEN European phase II clinical trials. Pediatr. Blood Cancer 6425–31 (2017).
Google Scholar
Moreno, L. et al. Bevacizumab, irinotecan, or topotecan added to temozolomide for children with relapsed and refractory neuroblastoma: results of the ITCC-SIOPEN BEACON-Neuroblastoma trial. J. Clin. Oncol. 421135–1145 (2024).
Google Scholar
Mody, R. et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 18946–957 (2017).
Google Scholar
Mody, R. et al. Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children’s Oncology Group. J. Clin. Oncol. 382160–2169 (2020).
Google Scholar
Lerman, B. J. et al. Progression-free survival and patterns of response in patients with relapsed high-risk neuroblastoma treated with irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol. 41508–516 (2023).
Google Scholar
Olgun, N. et al. Dinutuximab β plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: a single-center experience. Front. Oncol. 121041443 (2022).
Google Scholar
Raiser, P. et al. Chemo-immunotherapy with dinutuximab β in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter? EUR. J. Cancer 202114001 (2024).
Google Scholar
Gray, J. et al. BEACON-Immuno: results of the dinutuximab β (dB) randomization of the BEACON-Neuroblastoma phase 2 trial—a European Innovative Therapies for children with cancer (ITCC–International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial. J. Clin. Oncol. 4010002 (2022).
Google Scholar
Del Bufalo, F. et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N. Engl. J. Med. 3881284–1295 (2023).
Google Scholar
Morgenstern, D. A. et al. Risk stratification of high-risk metastatic neuroblastoma: a report from the HR-NBL-1/SIOPEN study. Pediatr. Blood Cancer 65E27363 (2018).
Google Scholar
Campbell, K. et al. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: a report from the Children’s Oncology Group. Cancer 1234224–4235 (2017).
Google Scholar
Yanik, G. A. et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s Oncology Group. J. Nucl. With. 54541–548 (2013).
Google Scholar
Moreno, L. et al. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: an International Neuroblastoma Risk Group project. Pediatr. Blood Cancer 68E28794 (2021).
Google Scholar
Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124188–195 (2014).
Google Scholar
Hayden, P. J. et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann. Oncol. 33259–275 (2022).
Google Scholar
Quintarelli, C. et al. Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma. Night. With. 31849–860 (2025).
Google Scholar
Chok, R. & Ramakrishna, S. Allogeneic approach unlocks CAR T cell benefits in solid tumors. Night. With. 31733–734 (2025).
Google Scholar
Mora, J. et al. Clinical and pathological evidence of anti-GD2 immunotherapy induced differentiation in relapsed/refractory high-risk neuroblastoma. Cancers (Basel) 131264 (2021).
Google Scholar
Park, J. R. et al. Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. Cancer 1283775–3783 (2022).
Google Scholar
Straathof, K. et al. Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma. Sci. Transl. Med. 12eabd6169 (2020).
Google Scholar
Heczey, A. et al. CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol. Ther. 252214–2224 (2017).
Google Scholar
Louis, C. U. et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 1186050–6056 (2011).
Google Scholar
Steffin, D. et al. Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature 637940–946 (2025).
Google Scholar
Zhou, X. et al. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood 1254103–4113 (2015).
Google Scholar
Applebaum, M. A. et al. Neuroblastoma survivors are at increased risk for second malignancies: a report from the International Neuroblastoma Risk Group Project. EUR. J. Cancer 72177–185 (2017).
Google Scholar
Haghiri, S. et al. Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue. Bone Marrow Transpl. 561984–1997 (2021).
Google Scholar
Bird, N., Scobie, N., Palmer, A. & Ludwinski, D. To transplant, or not to transplant? That is the question. A patient advocate evaluation of autologous stem cell transplant in neuroblastoma. Pediatr. Blood Cancer 69E29663 (2022).
Google Scholar
Quintarelli, C. et al. Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. Oncoimmunology 7E1433518 (2018).
Google Scholar
Park, J. R. et al. Revisions to the International Neuroblastoma Response Criteria: a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. J. Clin. Oncol. 352580–2587 (2017).
Google Scholar
Ladenstein, R. et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur. J. Nucl. Med. Mol. Imaging 45292–305 (2018).
Google Scholar
Lewington, V. et al. 123I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting method by an international panel. Eur. J. Nucl. Med. Mol. Imaging 44234–241 (2017).
Google Scholar
Zeytin, H. E., Tripathi, P. K., Bhattacharya-Chatterjee, M., Foon, K. A. & Chatterjee, S. K. Construction and characterization of DNA vaccines encoding the single-chain variable fragment of the anti-idiotype antibody 1A7 mimicking the tumor-associated antigen disialoganglioside GD2. Cancer Gene Ther. 71426–1436 (2000).
Google Scholar
Schemper, M. & Smith, T. L. A note on quantifying follow-up in studies of failure time. Control Clin. Trials 17343–346 (1996).
Google Scholar
What are the key eligibility criteria for patients to participate in the Phase 1/2 trial of GD2-targeted CAR T-cells?
Table of Contents
- 1. What are the key eligibility criteria for patients to participate in the Phase 1/2 trial of GD2-targeted CAR T-cells?
- 2. Advancing High-Risk Neuroblastoma Treatment: A Phase 1/2 Trial of GD2-Targeted CAR T Cells
- 3. Understanding high-Risk Neuroblastoma
- 4. What are CAR T-Cells? A Primer on Immunotherapy
- 5. GD2: The Target in Neuroblastoma CAR T-Cell Therapy
- 6. Phase 1/2 Trial Details: Evaluating Safety and Efficacy
- 7. Emerging Data and Trial Results (as of August 21, 2025)
- 8. Benefits of GD2-Targeted CAR T-Cell therapy
- 9. Practical Tips for Families Considering CAR T-Cell Therapy
Advancing High-Risk Neuroblastoma Treatment: A Phase 1/2 Trial of GD2-Targeted CAR T Cells
Understanding high-Risk Neuroblastoma
Neuroblastoma is a cancer that develops from immature nerve cells, most commonly affecting children. While some neuroblastomas are low-risk and may resolve on their own, high-risk neuroblastoma presents a meaningful challenge. According to Cancer Australia, the exact causes of neuroblastoma remain unclear, but research continues to identify contributing factors. high-risk cases often involve aggressive tumor growth, metastasis (spreading to other parts of the body), and resistance to conventional treatments like chemotherapy, surgery, and radiation. This is where innovative therapies like CAR T-cell therapy offer new hope.
What are CAR T-Cells? A Primer on Immunotherapy
Chimeric Antigen Receptor (CAR) T-cell therapy is a type of immunotherapy that harnesses the power of the patient’s own immune system to fight cancer. Here’s how it works:
- T-cell Collection: T-cells, a type of white blood cell crucial for immunity, are collected from the patient’s blood.
- Genetic Modification: In a laboratory, these T-cells are genetically engineered to express a chimeric antigen receptor (CAR).This CAR is specifically designed to recognize a protein found on the surface of neuroblastoma cells.
- Expansion: The modified CAR T-cells are grown in large numbers.
- Infusion: The expanded CAR T-cells are infused back into the patient, where they seek out and destroy cancer cells expressing the target protein.
GD2: The Target in Neuroblastoma CAR T-Cell Therapy
Many neuroblastoma cells express a disialoganglioside called GD2. GD2 is rarely found on normal cells, making it an ideal target for CAR T-cell therapy. GD2-targeted CAR T-cells are engineered to specifically recognize and bind to GD2, triggering an immune response against the tumor. This targeted approach minimizes damage to healthy tissues.
Phase 1/2 Trial Details: Evaluating Safety and Efficacy
Recent Phase 1/2 clinical trials are investigating the safety and efficacy of GD2-targeted CAR T-cell therapy in children and young adults with relapsed or refractory high-risk neuroblastoma. These trials typically involve:
Phase 1 (Safety): A small group of patients receives escalating doses of CAR T-cells to determine the maximum tolerated dose and identify potential side effects.
Phase 2 (Efficacy): A larger group of patients receives the established dose to assess the therapy’s effectiveness in shrinking tumors and improving survival rates.
Key aspects being evaluated in these trials include:
Overall Response Rate (ORR): The percentage of patients whose tumors shrink or disappear.
Duration of Response: How long the tumor remains under control.
Progression-Free Survival (PFS): The length of time during which the disease does not worsen.
Overall survival (OS): The length of time patients survive after treatment.
Cytokine Release Syndrome (CRS): A common side effect of CAR T-cell therapy, where the immune system releases a flood of cytokines, perhaps causing fever, flu-like symptoms, and organ dysfunction.
Neurotoxicity: Another potential side effect, involving neurological complications.
Emerging Data and Trial Results (as of August 21, 2025)
While specific results vary between trials, early data from several Phase 1/2 studies show promising activity. Many patients with relapsed/refractory high-risk neuroblastoma have experienced tumor regression following GD2-targeted CAR T-cell therapy.
Improved Response Rates: Studies have reported ORR ranging from 30% to 60% in heavily pre-treated patients.
durable Remissions: Some patients have achieved complete remissions that have lasted for extended periods.
Management of Side Effects: Researchers are developing strategies to effectively manage CRS and neurotoxicity, including the use of tocilizumab (an IL-6 receptor antagonist) and corticosteroids.
Benefits of GD2-Targeted CAR T-Cell therapy
Targeted Treatment: Specifically targets neuroblastoma cells expressing GD2, minimizing harm to healthy tissues.
Potential for Long-Term Remission: Offers the possibility of durable responses in patients who have failed other treatments.
Novel Approach: Provides a new treatment option for a challenging cancer with limited therapeutic options.
* Personalized Medicine: Utilizes the patient’s own immune cells, creating a personalized therapy.
Practical Tips for Families Considering CAR T-Cell Therapy
If you are considering CAR T-cell therapy for your child with high-risk neuroblastoma,here are some practical tips:
- find an Experienced Center: Seek treatment at a medical center with extensive experience in CAR T-cell therapy and neuroblastoma.
- Understand the Risks and Benefits: discuss the potential risks and benefits of the therapy with your child’s oncologist.
- prepare for Side Effects: Be prepared to manage potential side effects like CRS and
